Biopharma giant Gilead Sciences will shut down its office in Seattle's Eastlake neighborhood, the company confirmed to ...

RBC Capital analyst Brian Abrahams maintained a Hold rating on Gilead Sciences (GILD – Research Report) today and set a price target of $84.00.

The scope of Gilead Sciences' recent round of layoffs is coming into clearer view with the revelation that the company is ...

Fintel reports that on November 15, 2024, Wolfe Research initiated coverage of Gilead Sciences (NasdaqGS:GILD) with a ...

On Friday, Gilead Sciences, Inc. (GILD) stock saw a decline, ending the day at $88.4 which represents a decrease of $-3.71 or -4.03% from the prior close of $92.11. The stock opened at $91.71 and ...

Gilead Sciences, a Bay Area-headquartered biotech and pharmaceutical company, is laying off 104 workers in Foster City, with ...

Fintel reports that on November 14, 2024, Citigroup initiated coverage of Gilead Sciences (NasdaqGS:GILD) with a Buy ...

For the year to September 2024, Gilead Sciences had an accrual ratio of -0.24. That implies it has very good cash conversion, and that its earnings in the last year actually significantly ...

On Friday, Gilead Sciences, Inc. (NASDAQ:GILD) revealed data from a two-and-a-half-year interim analysis from the ongoing ...

Comprehensive SWOT analysis reveals Gilead Sciences Inc's strategic positioning in the pharmaceutical industry. Financial ...

TD Cowen analyst Tyler Van Buren maintained a Buy rating on Gilead Sciences (GILD – Research Report) today and set a price target of ...